| 1 |
Abeles AM, Pillinger MH, Solitar BM, et al., Narrative review:the pathophysiology of fibromyalgia. Ann Intern Med 2007; 146: 726-734.
DOI
ScienceOn
|
| 2 |
Goldenberg DL, Clauw DJ, Palmer RH, et al., Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010; 11: 180-194.
DOI
ScienceOn
|
| 3 |
Branco JC, Zachrisson O, Perrot S, et al., A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumaol 2010; 37: 851-9.
DOI
ScienceOn
|
| 4 |
Jones CK, Eastwood BJ, Need AB, et al., Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 2006; 51: 1172-1180.
DOI
ScienceOn
|
| 5 |
Obata H, Saito S, Koizuka S, et al., The monoamine-mediated antiallodynic effects ofintrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. AnesthAnalg 2005; 100: 1406-1410.
DOI
ScienceOn
|
| 6 |
Product information. Savella (milnacipran). New York, NY: Forest Pharmaceuticals, Inc., December 2009.
|
| 7 |
Puozzo C. Lens S, Reh C, et al., Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. ClinPharmacokinet 2005; 44: 977-988.
DOI
ScienceOn
|
| 8 |
Gendreau RM, Thorn MD, Gendreau JF, et al., Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32: 1975-1985.
|
| 9 |
Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. IntClinPsychopharmacol 2002; 17(Suppl 1): S25-S35.
DOI
|
| 10 |
Vaishnavi SN, Nemeroff CB, Plott SJ, et al., Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004; 55: 320-322.
DOI
ScienceOn
|
| 11 |
Clauw DJ, Mease P, Palmer RH, et al., Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clnical trial. ClinTher 2008; 30: 1988-2004.
DOI
ScienceOn
|
| 12 |
Mease PJ, Clauw DJ, Gendreau RM, et al., The efficacy and safety of milnacipran for the treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36: 398-409.
DOI
ScienceOn
|
| 13 |
American College of Rheumatology. Patient education for fibromyalgia. www.rheumatology.org/public/factsheets/diseases_and_conditions/fibromyalgia.asp?aud=pat (accessed July 25, 2010).
|
| 14 |
Wolfe F, Ross K, Anderson J, et al., The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
DOI
ScienceOn
|
| 15 |
Kim SH, Bae GR, Lim HS. Prevalence and risk factors of fibromyalgia syndrome and chronic widespread pain in two communities in Korea - First report in Korean. J Korean Rheumatism Assoc 2006; 13: 18-25.
|
| 16 |
Wolfe F, Ross K, Anderson J, et al., Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995; 22: 151-6.
|
| 17 |
Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care 2009; 15: S197-218.
|
| 18 |
Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res ClinRheumatol 2007; 21: 499-511.
DOI
|
| 19 |
WolfeF, Smythe H, Yunus M, et al., The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-172.
DOI
ScienceOn
|
| 20 |
Bennett R. Fibromyalgia: present to future. CurrRheumatol Rep 2005; 7: 371-376.
DOI
ScienceOn
|
| 21 |
Abeles M, Solitar BM, Pillinger MH, et al., Update on fibromyalgia therapy. Am J Med 2008; 121: 555-561.
DOI
ScienceOn
|
| 22 |
Savella. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc; expires 2010 Dec 31 (accessed July 26, 2010).
|
| 23 |
Forest Laboratories, Inc. Forest Laboratories, Inc. and Cypress Bioscience, Inc. announce commercial availability ofSavella. www.frx.com/news/ PressRelease. aspx/ (accessed July 26, 2010)
|
| 24 |
Arnold LM, Gendreau RM, Palmer RH, et al., Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 2745-2756.
DOI
ScienceOn
|
webmaster
